Please assess the completion status of the following clinical trial:

Trial Title: CYP3A4 Activity and Mineral Homeostasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with no history of significant medical conditions including cardiac, pulmonary, gastrointestinal, or renal disease, HIV, diabetes mellitus or Hepatitis B or C~* Subjects will be males or females 18-60 years of age~* Subjects must read and understand English~* Subjects must be able to provide informed consent~* Subjects must be willing to avoid prescription medications, OTC drugs, dietary supplements and foods that are known to modulate CYP3A4 expression or activity~* Subjects must be willing to maintain a consistent consumption of calcium and Vitamin D during the study and maintain a daily logbook of their dietary consumption~* Women not currently pregnant or lactating. In addition, women participants of childbearing age must be willing to utilize a barrier method of birth control (sterilization will be acceptable)~* Subjects will have no known allergies to the study drugs to be used~* Subject's corrected QTc interval obtained by electrocardiogram will be ≤ 430 ms in men or ≤ 450 ms in women~Exclusion Criteria:~* Subjects with any significant chronic medical condition, including cardiac, pulmonary, gastrointestinal, or renal disease, HIV, diabetes mellitus or Hepatitis B or C~* Subjects less than 18 or greater than 60 years of age~* Subjects unable to read and understand English~* Subjects unable to provide informed consent~* Subjects unable to avoid prescription medications, OTC drugs, dietary supplements and foods that are known to modulate CYP3A4 expression or activity~* Subjects not willing to maintain a consistent consumption of calcium and Vitamin D during the study and maintain a daily logbook of their dietary consumption~* Women who are pregnant or lactating and women participants of childbearing age not willing to utilize a barrier method of birth control (sterilization will be acceptable)~* Subjects with allergies to rifampin, clarithromycin or grapefruit juice~* Potential participants will be excluded if they are concurrently participating in another research study~* Subjects with corrected QTc interval \> 430 ms in men or \> 450 ms in women on electrocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Water (Type: PLACEBO_COMPARATOR): 200 mL of water once a day for 14 days
- Rifampin (Type: ACTIVE_COMPARATOR): Rifampin 600 mg once a day for 14 days
- Grapefruit Juice (Type: ACTIVE_COMPARATOR): 200 mL of grapefruit juice once a day for 14 days
- Grapefruit Juice Plus Rifampin (Type: ACTIVE_COMPARATOR): 200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
- Clarithromycin (Type: ACTIVE_COMPARATOR): Clarithromycin 250 mg twice a day for 14 days
- Clarithromycin Plus Rifampin (Type: ACTIVE_COMPARATOR): Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).